215 related articles for article (PubMed ID: 18534121)
1. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
Paterson A; McCloskey E; Redzepovic J; Ott I; Gust R
J Int Med Res; 2008; 36(3):400-13. PubMed ID: 18534121
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Schivazappa C; Berto P; Baldini E; Barni S; Dauria G; Cortesi E
Recenti Prog Med; 2008 Jan; 99(1):27-31. PubMed ID: 18389868
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil.
Cunio Machado Fonseca M; Tannus Branco de Araújo G; Etto H; Schiola A; Santoni N; Machado M
Clin Ther; 2011 Nov; 33(11):1769-1780.e2. PubMed ID: 22019346
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Machado M; Cruz LS; Tannus G; Fonseca M
Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
[TBL] [Abstract][Full Text] [Related]
10. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
Caffo O
Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
[No Abstract] [Full Text] [Related]
11. Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Major PP; Lipton A; Berenson J; Hortobagyi G
Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the role of bisphosphonates in metastatic disease.
Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
15. [Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Bartl R
Dtsch Med Wochenschr; 2008 Nov; 133(48):2530. PubMed ID: 19021088
[No Abstract] [Full Text] [Related]
16. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Terpos E; Dimopoulos MA; Berenson J
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
[TBL] [Abstract][Full Text] [Related]
17. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
18. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
20. Dosing regimens and main adverse events of bisphosphonates.
Body JJ
Semin Oncol; 2001 Aug; 28(4 Suppl 11):49-53. PubMed ID: 11544576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
